NEW YORK — Immune profiling firm Immunai said on Thursday that it has acquired single-cell genomics software company Dropprint Genomics for an undisclosed amount.
New York City-based Immunai, which has offices in San Francisco and Tel Aviv, said the acquisition is providing it with technologies San Francisco-based Dropprint has developed for handling the computational demands of large-scale single-cell sequencing and for more cost-effectively processing large numbers of patients samples.